RBF Capital’s Harvard Bioscience HBIO Stock Holding History

RBF Capital’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$77.9K	Hold	16,000	–	–	﹤0.01%	482
2025 Q4	$107K	Hold	16,000	–	–	﹤0.01%	537
2025 Q3	$70.2K	Hold	16,000	–	–	﹤0.01%	568
2025 Q2	$71K	Sell	16,000 -2,091	-12%	-$8.74K	﹤0.01%	590
2025 Q1	$102K	Buy	+18,091	New	+$232K	0.01%	547
2015 Q2	–	Sell	-2,000	Closed	-$116K	–	332
2015 Q1	$116K	Hold	2,000	–	–	0.02%	277
2014 Q4	$113K	Hold	2,000	–	–	0.02%	272
2014 Q3	$82K	Sell	2,000 -213	-10%	-$9.8K	0.02%	273
2014 Q2	$101K	Sell	2,213 -1,176	-35%	-$49.4K	0.02%	266
2014 Q1	$161K	Hold	3,389	–	–	0.04%	254
2013 Q4	$159K	Sell	3,389 -1,081	-24%	-$47.2K	0.04%	259
2013 Q3	$178K	Hold	4,470	–	–	0.05%	246
2013 Q2	$159K	Buy	+4,470	New	+$171K	0.05%	244

Other funds holding HBIO

WCM

Weber Capital Management San Francisco, California $100M AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

CCM

Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return

MIM

Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RBF Capital's HBIO Position: Q1 2026 in Review

RBF Capital held its Harvard Bioscience (HBIO) position steady in Q1 2026 at 16,000 shares worth $77.9K. The position accounts for ﹤0.01% of the portfolio, ranked #482.

RBF Capital first reported a position in HBIO in Q2 2013 and has held it in 13 quarters since. The position peaked at $178K in Q3 2013. 36 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.

RBF Capital held 16,000 shares of Harvard Bioscience worth $77.9K as of Q1 2026.
RBF Capital left its Harvard Bioscience share count unchanged in Q1 2026.
Harvard Bioscience made up ﹤0.01% of RBF Capital's portfolio in Q1 2026, its #482 holding.
RBF Capital first reported a position in Harvard Bioscience in Q2 2013 and has held it in 13 quarters since.
RBF Capital's Harvard Bioscience position peaked at $178K in Q3 2013.
36 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.

Based on RBF Capital's 13F filing for Q1 2026, filed 15 May 2026.